[Is prognosis of acute lymphoblastic leukemia at a turning point?].
D000917:Antibody Formation; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D003596:Cytosine / Q000627:therapeutic use; D006801:Humans; D007167:Immunotherapy; D007518:Isoantibodies; D007945:Leukemia, Lymphoid / Q000276:immunology / Q000628:therapy*; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D009163:Mycobacterium bovis; D011241:Prednisone / Q000627:therapeutic use*; D011379:Prognosis; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D007518:Isoantibodies; D014750:Vincristine; D003596:Cytosine; D003520:Cyclophosphamide; D015122:Mercaptopurine; D011241:Prednisone; D008727:Methotrexate
La prognosi della leucemia acuta linfoblastica è ad una svolta?